Weight Loss

Patients who were prescribed phentermine after losing fewer than 20 pounds while on a GLP-1 receptor agonist were more likely to lose weight 1 year after GLP-1 discontinuation than those who were not prescribed phentermine, recent findings show.

The net benefit of GLP-1 receptor agonists in adults with overweight or obesity who do not have diabetes depends on their weight loss target and willingness to accept harms, according to researchers.

Adults with obesity lost 10.2% of their body weight at 4 years with the GLP-1 receptor agonist semaglutide, according to an analysis of data from the SELECT trial.

WASHINGTON — The Primary Obesity Surgery Endoluminal 2.0 procedure is a “safe, effective and durable option” for weight loss and improvement in obesity-related conditions, according to a presenter.

The disease of obesity often brings cardiometabolic consequences, including hypertension, which remains the most potent and predictive risk factor for cardiovascular disease.

Today, we are closer than ever to achieving the weight loss seen with bariatric surgery, and we are starting to see emerging evidence of cardiovascular risk reduction, type 2 diabetes remission, improvement in heart failure with preserved ejection fraction (HFpEF) and more. This “new” class of medications has been around for more than 18 years. We know the safety profiles; they are manageable.

Last month, the Obesity Medicine Association held its annual conference, where clinicians across the country came together to discuss the latest developments in obesity care.

LONG BEACH, Calif. — A patient on dialysis who lost weight after bariatric surgery was able to reduce the number of home hemodialysis sessions from five to four treatments without adverse outcomes, researchers said here.

A 12-month self-guided, low-intensity, video-based lifestyle intervention helped patients with COPD and obesity lose weight, according to results published in Annals of the American Thoracic Society.

NEW ORLEANS — Nearly all adults who lose less than 5% of their body weight with tirzepatide at 12 weeks were able to achieve at least a 5% weight loss by 72 weeks, according to a post-hoc analysis of the SURMOUNT-1 trial.